Adriana Matutino Kahn, MD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Research
Publications
Featured Publications
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyDisease-free survivalBetter disease-free survivalNeoadjuvant chemotherapyBreast cancerOverall survivalAdvanced breast cancerClinical stage IIIBetter overall survivalAdvanced BC patientsTherapy delayBC patientsClinical impactEarly initiationRadiation therapyStage IIIPatientsSurgeryOptimal timingWeeksChemotherapyFirm conclusionsCancerSurvivalInitiationIntratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and LettersCDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.Peer-Reviewed Original ResearchTriple-negative breast cancerProgression-free survivalBreast cancerCDK4/6 inhibitorsHormone receptor-positive HER2-negative diseaseCyclin-dependent kinase 4/6 inhibitorsPositive human epidermal growth factor receptor 2Human epidermal growth factor receptor 2Epidermal growth factor receptor 2HER2-negative diseaseGrowth factor receptor 2Metastatic breast cancer therapyNegative breast cancerBreast cancer therapyFactor receptor 2Preclinical evidenceClinical dataReceptor 2Later linesHormone receptorsCancerCancer therapyCell linesInhibitorsCDK inhibitorsThe impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment.
Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.Peer-Reviewed Original ResearchBreast cancerDifferent age groupsCurative treatmentAge groupsRetrospective cross-sectional analysisAnti-hormonal therapyBreast conserving surgeryCancer Patient QuestionnaireQuality of lifeImpact of ageCross-sectional analysisHigh financial burdenSurvivorship careConserving surgeryPatient questionnaireCurative therapySecond cancersLess painQOL scoresInvasive diseaseQoL dataHigh prevalenceStage 0Radiation therapyOngoing anxietyStrategies to mitigate the toxicity of cancer therapeutics
Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. Advances In Cancer Research 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.Peer-Reviewed Original ResearchConceptsAromatase inhibitor-induced musculoskeletal symptomsChemotherapy-induced peripheral neuropathyCancer-related cognitive impairmentCancer treatment symptomsOral mucosal toxicityImmune checkpoint inhibitionTyrosine kinase inhibitorsCancer therapeuticsGastrointestinal toxicityMucosal toxicityAdverse eventsHormone therapySystemic therapyTreatment toxicityPeripheral neuropathyCheckpoint inhibitionSymptom managementMusculoskeletal symptomsRenal toxicityTreatment symptomsOcular toxicityTreatment modalitiesTraditional chemotherapyCognitive impairmentMonoclonal antibodiesComparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada.
Matutino A, Pereira A, Kornaga E, Lupichuk S, Verma S. Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada. Journal Of Clinical Oncology 2018, 36: e18617-e18617. DOI: 10.1200/jco.2018.36.15_suppl.e18617.Peer-Reviewed Original ResearchIntratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPD-L1 expressionBreast cancerPD-L1Metastatic triple-negative breast cancerPD-L1 positive casesEarly-stage breast cancerPD-L1 protein expressionImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusProtein expressionWhole study populationPrimary breast tumorsNegative breast cancerConcordant negative resultsCheckpoint inhibitorsMultiple biopsiesPositive cancersCohen's kappa coefficientStudy populationE1L3N antibodyDiscordance rateBreast tumorsPositive casesOutcomes of acute pulmonary embolism in hospitalized patients with cancer.
Shalaby K, Kahn A, Silver ES, Kim MJ, Balakumaran K, Kim AS. Outcomes of acute pulmonary embolism in hospitalized patients with cancer. BMC Pulm Med 2022, 22: 11. PMID: 34986814, DOI: 10.1186/s12890-021-01808-9.Peer-Reviewed Original ResearchSurvival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status.
Savard MF, Kornaga EN, Kahn AM, Lupichuk S. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status. Curr Oncol 2022, 29: 383-391. PMID: 35049708, DOI: 10.3390/curroncol29010034.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Adriana Matutino Kahn, MD, is a medical oncologist and hematologist who specializes in caring for people with breast cancer. She focuses on treatments that aim to improve outcomes and quality of life, including innovations in drug development.
As an assistant professor of medicine (medical oncology) at Yale School of Medicine, Dr. Kahn leads research on breast cancer and serves as the principal investigator on several clinical trials for new potential therapies. She has received major awards from the American Association of Cancer Research and the American Society of Clinical Oncology in recognition of her work.
Dr. Kahn earned her medical degree from the Universidade Federal da Bahia in Brazil before completing a residency in internal medicine at the University of Connecticut. She also pursued a residency and a medical oncology fellowship at the Universidade de São Paulo, followed by a fellowship in breast cancer in Canada, and an additional fellowship in medical oncology at Yale School of Medicine.
Clinical Specialties
Medical Oncology
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale MedicineInflammatory Breast Cancer
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- December 17, 2024
Yale Cancer Center presents advances in breast cancer at the San Antonio Breast Cancer Symposium
- October 07, 2024
Caring for Metastatic Breast Cancer: A Conference for Patients and Caregivers
- July 17, 2024Source: Everyday Health
Is My Breast Rash a Sign of Cancer?
- June 19, 2024Source: MedPage Today
Breast Cancer Highlights From ASCO 2024
Get In Touch
Contacts
Appointment Number
Mailing Address
Center for Breast Cancer
300 George St, Room 120
New Haven, CT 06511
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.